← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT06996561

NCT06996561 Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06996561
Status Recruiting
Phase Phase 2, Phase 3
Sponsor Dr. Asma Abdus Salam
Condition Cholecystectomy
Study Type INTERVENTIONAL
Enrollment 263 participants
Start Date 2025-09-01
Primary Completion 2027-01-01

Trial Parameters

Condition Cholecystectomy
Sponsor Dr. Asma Abdus Salam
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 263
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2025-09-01
Completion 2027-01-01
Interventions
Nalbuphine InjectionNext Generation Sequencingwhole exome sequencing

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this study is to identify the genes as well as their association with Nalbuphine. This will help the investigator to identify opioid vulnerability in Pakistani population in the postoperative patients and will contribute to overcoming the opioid crisis, resulting in better and safer outcomes. Research question is: Is there any association between the underlying genetic variations and the analgesic efficacy of Nalbuphine in postoperative patients? The Research Objectives are 1. To identify the underlying genes in postoperative patients having pain. 2. To find an association between identified genes and nalbuphine clinical efficacy. Procedure: After the written informed consent adult men and women will be enrolled in the study. On the day of surgery in the preoperative area, a 5 ml blood sample will be drawn before surgery and will be sent to laboratory for analysis. After routine hemodynamic monitoring in the operative room, general anesthesia will be given including nalbuphine. Standard routine anesthesia monitoring will be done and maintained while monitoring heart rate, ECG, NIBP oxygen saturation, ETCO2 and temperature. Incremental analgesia will be provided whenever needed. After extubation and shifting to recovery room the 2nd sample of blood will be taken and will be sent for analysis. Pain score, nausea vomiting, sedation, requirement of analgesia will be assessed till 24 hours postoperatively.

Eligibility Criteria

Inclusion Criteria: 1. All adult men or women 2. Age 18 to 70 years 3. ASA criteria 1,2 and 3 4. Abdomino-pelvic surgeries (open hernia repair, appendicectomy, open cholecystectomy, laparotomy, hysterectomy, cystectomy) lasting 2-4 hours Exclusion Criteria: 1. Surgical procedure duration lasting more than 4 hours 2. Patients taking anti fungal fluconazole, anticoagulant (Warfarin or Clopidogrel) SNRI (Amitryptalline), Rifampicin or Buprenorphine, 3. History of hypersensitivity or allergy to opioids, 4. Pregnant or breastfeeding mothers, 5. History of narcotic dependency, addiction, and withdrawal 6. Patients experiencing any adverse side effects or complications during surgical procedure requiring intensive care admission 7. Refusing to participate in the study 8. Surgical procedures utilizing other modes of intraoperative analgesia e.g epidural analgesia or nerve blocks

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology